A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503522-40-00

Acronym

ANB032-201

Enrollment

Registered

2023-09-12

Start date

Unknown

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Brief summary

Mean change from Baseline in Eczema Area and Severity Index (EASI) at Week 14

Interventions

DRUGPlacebo matching IMP

DRUGHYDROCORTISONE

DRUGALCLOMETASONE

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Mean change from Baseline in Eczema Area and Severity Index (EASI) at Week 14	—

Countries

Czechia, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026